18-year change in serum intact fibroblast growth factor 23 from midlife to late life and risk of mortality: the ARIC Study.

Serum intact FGF23 change from midlife to late life was associated with subsequent risk of mortality independent of decline in kidney function. Our findings further support the implications of FGF23 beyond its association with kidney function.